Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

PHASE3RecruitingINTERVENTIONAL
Enrollment

582

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

January 31, 2032

Conditions
Ovarian Cancer
Interventions
DRUG

Trastuzumab Deruxtecan

T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)

DRUG

Bevacizumab

Bevacizumab will be administered at a dose of 15/mg/kg IV Q3W

Trial Locations (59)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

21204

RECRUITING

Greater Baltimore Medical Center, Towson

27599

RECRUITING

UNC Hospital, Chapel Hill

33316

RECRUITING

Broward Health Medical Center, Fort Lauderdale

45459

RECRUITING

Miami Valley Hospital South, Centerville

46202

RECRUITING

Indiana University, Indianapolis

57105

RECRUITING

Avera Medical Group Gynecologic, Sioux Falls

71103

RECRUITING

Trials365 LLC, Shreveport

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai Shi

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

07652

RECRUITING

Valley Health System, Paramus

Unknown

RECRUITING

UZ Leuven, Leuven

RECRUITING

Fundação Doutor Amaral Carvalho, Jaú

RECRUITING

Liga Norte-Rio-Grandense Contra o Cancer, Natal

RECRUITING

Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Hospital Mae de Deus, Porto Alegre

RECRUITING

BP A Beneficencia Portuguesa de Sao Paulo, São Paulo

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

The First Hospital of Jilin University, Changchun

RECRUITING

Chongqing Cancer Hospital, Chongqing

RECRUITING

The Second Hospital of Dalian Medical University, Dalian

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

RECRUITING

Hainan General Hospital, Haikou

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

Women's Hospital School of Medicine Zhejiang University, Hangzhoushi

RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Jiangxi Maternal and Child Health Hospital, Nanchang

RECRUITING

Zhong Da Hospital, Southeast University, Nanjing

RECRUITING

Guangxi Medical University Cancer Hopstial, Nanning

RECRUITING

Affiliated Hospital (Suzhou First People's Hospital), Suzhou

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

RECRUITING

Tongji Hospital Tongji Medical College of HUST, Wuhan

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

RECRUITING

The Lady Davis Carmel Medical Center, Haifa

RECRUITING

Kurume University Hospital, Kurume-shi

RECRUITING

Aichi Cancer Center Hospital, Nagoya

RECRUITING

Niigata Cancer Center Hospital, Niigata

RECRUITING

Kindai University Hospital, Osakasayama-shi

RECRUITING

Shizuoka Cancer Center, Sunto-gun

RECRUITING

Keimyung University Dongsan Hospital, Daegu

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

RECRUITING

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

RECRUITING

Chang Gung Memorial Hospital, Linkou Taoyuan

RECRUITING

Taichung Veterans General Hospital, Taichung

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

MacKay Memorial Hospital- Taipei Branch, Taipei

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei

673-8558

RECRUITING

Hyogo Cancer Center, Akashi

104-0045

RECRUITING

National Cancer Center Hospital, Chūōku

960-1295

RECRUITING

Fukushima Medical University Hospital, Fukushima

350-1298

RECRUITING

Saitama Medical University International Medical Center, Hidaka-Shi

135-8550

RECRUITING

Cancer Institute Hospital of JFCR, Kōtoku

700-8558

RECRUITING

Okayama University Hosptial, Okayama

003-0804

RECRUITING

NHO Hokkaido Cancer Center, Sapporo

028-3695

RECRUITING

Iwate Medical University Hospital, Shiwa-Gun

514-8507

RECRUITING

Mie University Hospital, Tsu

990-9585

RECRUITING

Yamagata University Hospital, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT06819007 - Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Biotech Hunter | Biotech Hunter